Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

This study is evaluating a combined approach for treating advanced liver cancer (hepatocellular carcinoma, or HCC) using locoregional therapy — procedures that target tumors directly in the liver — together with bevacizumab (a drug that cuts off blood supply to tumors) and a checkpoint inhibitor (an immunotherapy drug). Researchers are studying whether this combination improves survival. **You may be eligible if:** - You are between 18 and 75 years old - You have been diagnosed with HCC at an intermediate or advanced stage (BCLC stage B or C) - Your liver function is relatively preserved (Child-Pugh A or B) - Your physical fitness score (ECOG) is 0–2 - Your blood counts and organ function are within acceptable levels **You may NOT be eligible if:** - Your liver function is severely impaired (Child-Pugh C) - Your physical status is too poor (ECOG above 2) - Your blood counts or organ function are below acceptable thresholds Talk to your doctor to see if this trial is right for you.